

wherein

X and Z each represent CH or N;

R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>, which may be the same or different, represent a hydrogen atom, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, nitro, or amino, which C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl are optionally substituted by a halogen atom; hydroxyl; C<sub>1-4</sub> alkoxy; C<sub>1-4</sub> alkoxy carbonyl; amino on which one or two hydrogen atoms are optionally substituted by C<sub>1-4</sub> alkyl optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy; group R<sup>12</sup>R<sup>13</sup>N-C(=O)-O- wherein R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, represent a hydrogen atom or C<sub>1-4</sub> alkyl which alkyl is optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy; or group R<sup>14</sup>-(S)m- wherein R<sup>14</sup> represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C<sub>1-4</sub> alkyl and m is 0 or 1;


R<sup>4</sup> represents a hydrogen atom;

R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup>, which may be the same or different, represent a hydrogen atom, a halogen atom, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, or amino, provided that R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> do not simultaneously represent a hydrogen atom;

R<sup>9</sup> and R<sup>10</sup>, which may be the same or different, represent a hydrogen atom, C<sub>1-6</sub> alkyl, or C<sub>1-4</sub> alkyl carbonyl, the alkyl portion of which C<sub>1-6</sub> alkyl or C<sub>1-4</sub> alkyl carbonyl is optionally substituted by a halogen atom; C<sub>1-4</sub> alkoxy; amino which is optionally substituted by C<sub>1-4</sub> alkyl optionally substituted by C<sub>1-4</sub> alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

*B* 1 R<sup>11</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl (which C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl each are optionally substituted by a halogen atom or C<sub>1-6</sub> alkoxy), or R<sup>15</sup>-(CH<sub>2</sub>)<sub>n</sub>- wherein n is an integer of 0 to 4 and R<sup>15</sup> represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C<sub>1-6</sub> alkyl, or C<sub>1-6</sub> alkoxy and is optionally condensed with another saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

*B* 2 5. (Amended) A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:



wherein

X represents CH or N;

R<sup>21</sup> and R<sup>22</sup>, which may be the same or different, represent unsubstituted C<sub>1-6</sub> alkoxy or group R<sup>31</sup>-(CH<sub>2</sub>)<sub>p</sub>-O- wherein R<sup>31</sup> represents a halogen atom, hydroxyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkoxycarbonyl, amino on which one or two hydrogen atoms are optionally substituted by C<sub>1-4</sub> alkyl optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy, group R<sup>12</sup>R<sup>13</sup>N-C(=O)-O- wherein R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, represent a hydrogen atom or C<sub>1-4</sub> alkyl which alkyl is optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy, or group R<sup>14</sup>-(S)m- wherein R<sup>14</sup> represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C<sub>1-4</sub> alkyl and m is 0 or 1; and p is an integer of 1 to 6;

*B2*  
 $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$ , which may be the same or different, represent a hydrogen atom, a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio, nitro, or amino, provided that  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ , and  $R^{26}$  do not simultaneously represent a hydrogen atom;

$R^{27}$  and  $R^{28}$ , which may be the same or different, represent a hydrogen atom,  $C_{1-6}$  alkyl, or  $C_{1-4}$  alkylcarbonyl, the alkyl portion of which  $C_{1-6}$  alkyl or  $C_{1-4}$  alkylcarbonyl is optionally substituted by a halogen atom;  $C_{1-4}$  alkoxy; amino which is optionally substituted by  $C_{1-4}$  alkyl optionally substituted by  $C_{1-4}$  alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

$R^{29}$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or  $C_{2-6}$  alkynyl (which  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl each are optionally substituted by a halogen atom or  $C_{1-4}$  alkoxy), or  $R^{32}$ - $(CH_2)^q$ - wherein  $q$  is an integer of 0 to 4 and  $R^{32}$  represents a saturated or unsaturated six-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom,  $C_{1-4}$  alkyl, or  $C_{1-4}$  alkoxy and is optionally condensed with another saturated or unsaturated five- or six-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

*B3*  
51. (Twice Amended) A method for treating a disease selected from the group consisting of malignant tumor, diabetic ~~retinopathy~~, chronic rheumatism, psoriasis, and atherosclerosis, comprising the step of administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.

Please add the following claims.

*B4*  
--53. (New) The method of claim 51, wherein the disease is Kaposi's sarcoma.

54. (New) The compound according to claim 1, wherein  $R^1$  represents a hydrogen atom and  $R^2$  and  $R^3$  represent unsubstituted  $C_{1-4}$  alkoxy.

55. (New) The compound according to claim 1, wherein R<sup>5</sup>, R<sup>7</sup>, and R<sup>8</sup> represent a hydrogen atom and R<sup>6</sup> represents a chlorine atom.

*B4*  
56. (New) The compound according to claim 1, wherein R<sup>14</sup> represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

57. (New) The compound according to claim 1, wherein R<sup>15</sup> represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

58. (New) The compound according to claim 1, wherein R<sup>1</sup> represents a hydrogen atom, R<sup>2</sup> and R<sup>3</sup> represent unsubstituted C<sub>1-4</sub> alkoxy, R<sup>5</sup>, R<sup>7</sup>, and R<sup>8</sup> represent a hydrogen atom, R<sup>6</sup> represents a chlorine atom, R<sup>9</sup> and R<sup>10</sup> represent a hydrogen atom, and R<sup>11</sup> represents R<sub>15</sub>-(CH<sub>2</sub>)<sub>n</sub>- wherein n represents 0 (zero) and R<sub>15</sub> represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

59. (New) The compound according to claim 1, which is N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propylurea.—

#### SUPPORT FOR THE AMENDMENTS

Claims 1 and 5 have been amended for clarity. Newly-added Claim 53 is supported by original Claim 51. The amendment to Claim 51 and newly added Claims 54-59 are supported by the specification at pages 1-200, especially pages 4-6 and 91. No new matter is believed to have been added to this application by these amendments.

#### REMARKS

Claims 1-48 and 51-59 are pending. Favorable reconsideration is respectfully requested.